Literature DB >> 30257081

A Retrospective Comparative Effectiveness Study of Medications for Posttraumatic Stress Disorder in Routine Practice.

Brian Shiner1,2,3, Christine Leonard Westgate2, Jiang Gui4, Shira Maguen5, Yinong Young-Xu3,6, Paula P Schnurr3,7, Bradley V Watts3,8.   

Abstract

OBJECTIVE: Fluoxetine, paroxetine, sertraline, topiramate, and venlafaxine have consistently shown efficacy for posttraumatic stress disorder (PTSD) in meta-analyses of randomized controlled trials. However, no study has compared the effectiveness of these agents in routine clinical practice. We conducted a retrospective comparative effectiveness study of these 5 medications using electronic medical record data.
METHODS: We identified 2,931 Department of Veterans Affairs outpatients initiating treatment for PTSD between fiscal years 2004 and 2013 who received 1 of the 5 medications at an adequate dose and duration, combined with baseline and endpoint PTSD Checklist (PCL) measurements. Patients were identified based on clinical diagnoses of PTSD (DSM-IV criteria). We weighted participants in order to balance pretreatment characteristics. We compared continuous changes on total PCL score, symptom cluster scores, and sleep items, as well as categorical changes including reliable improvement and loss of PTSD diagnosis, using weighted regression analyses. We conducted exploratory analysis to determine whether any patient characteristics or service use variables predicted loss of PTSD diagnosis.
RESULTS: Patients improved by a mean of 5-6 points on the PCL over approximately 6 months of treatment. While half of patients had a reliable improvement of 5 points or more on the PCL, less than a fifth achieved loss of PTSD diagnosis. There were no differences between medications. The only significant (P < .001) predictor of loss of PTSD diagnosis was concurrent treatment with evidence-based psychotherapy.
CONCLUSIONS: Available evidence-based medications for PTSD are equally effective in clinical practice. Although effective, our data suggest that patients choosing medication treatment for PTSD should consider concurrent treatment with evidence-based psychotherapy in order to maximize their chances of meaningful improvement. © Copyright 2018 Physicians Postgraduate Press, Inc.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30257081      PMCID: PMC6217812          DOI: 10.4088/JCP.18m12145

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   5.906


  33 in total

1.  Why observational studies should be among the tools used in comparative effectiveness research.

Authors:  Nancy A Dreyer; Sean R Tunis; Marc Berger; Dan Ollendorf; Pattra Mattox; Richard Gliklich
Journal:  Health Aff (Millwood)       Date:  2010-10       Impact factor: 6.301

2.  Using administrative data to identify mental illness: what approach is best?

Authors:  Susan M Frayne; Donald R Miller; Erica J Sharkansky; Valerie W Jackson; Fei Wang; Jewell H Halanych; Dan R Berlowitz; Boris Kader; Craig S Rosen; Terence M Keane
Journal:  Am J Med Qual       Date:  2009-10-23       Impact factor: 1.852

3.  Sensitivity of the SF-36 to PTSD symptom change in veterans.

Authors:  Brian Shiner; Bradley V Watts; Andrew Pomerantz; Yinong Young-Xu; Paula P Schnurr
Journal:  J Trauma Stress       Date:  2011-02

4.  Treatment adherence in cognitive processing therapy for combat-related PTSD with history of mild TBI.

Authors:  Jeremy J Davis; Kristen H Walter; Kathleen M Chard; R Bruce Parkinson; Wes S Houston
Journal:  Rehabil Psychol       Date:  2013-02

Review 5.  Inclusion and exclusion criteria in randomized controlled trials of psychotherapy for PTSD.

Authors:  Julia M Ronconi; Brian Shiner; Bradley V Watts
Journal:  J Psychiatr Pract       Date:  2014-01       Impact factor: 1.325

6.  Exploring the efficacy of a residential treatment program incorporating cognitive processing therapy-cognitive for veterans with PTSD and traumatic brain injury.

Authors:  Kathleen M Chard; Jeremiah A Schumm; Susan M McIlvain; Gregory W Bailey; R Bruce Parkinson
Journal:  J Trauma Stress       Date:  2011-05-27

7.  Observational Evidence for Buprenorphine's Impact on Posttraumatic Stress Symptoms in Veterans With Chronic Pain and Opioid Use Disorder.

Authors:  Karen H Seal; Shira Maguen; Daniel Bertenthal; Steven L Batki; Joan Striebel; Murray B Stein; Erin Madden; Thomas C Neylan
Journal:  J Clin Psychiatry       Date:  2016-09       Impact factor: 4.384

8.  Anticonvulsant Medication Use in Veterans With Posttraumatic Stress Disorder.

Authors:  Brian Shiner; Christine Leonard Westgate; Nancy C Bernardy; Paula P Schnurr; Bradley V Watts
Journal:  J Clin Psychiatry       Date:  2017-05       Impact factor: 5.906

9.  Initiation of pharmacotherapy for post-traumatic stress disorder among veterans from Iraq and Afghanistan: a dimensional, symptom cluster approach.

Authors:  Ilan Harpaz-Rotem; Robert Rosenheck; Somaia Mohamed; Robert Pietrzak; Rani Hoff
Journal:  BJPsych Open       Date:  2016-09-09

10.  Dual equipoise shared decision making: definitions for decision and behaviour support interventions.

Authors:  Glyn Elwyn; Dominick Frosch; Stephen Rollnick
Journal:  Implement Sci       Date:  2009-11-18       Impact factor: 7.327

View more
  7 in total

1.  Using patient-reported outcomes to understand the effectiveness of guideline-concordant care for post-traumatic stress disorder in clinical practice.

Authors:  Brian Shiner; Jiang Gui; Christine Leonard Westgate; Paula P Schnurr; Bradley V Watts; Sarah L Cornelius; Shira Maguen
Journal:  J Eval Clin Pract       Date:  2019-05-21       Impact factor: 2.431

2.  Comparing Medications for DSM-5 PTSD in Routine VA Practice.

Authors:  Brian Shiner; Christine E Leonard; Jiang Gui; Sarah L Cornelius; Paula P Schnurr; Jessica E Hoyt; Yinong Young-Xu; Bradley V Watts
Journal:  J Clin Psychiatry       Date:  2020-10-13       Impact factor: 4.384

3.  Integrating human brain proteomes with genome-wide association data implicates novel proteins in post-traumatic stress disorder.

Authors:  Thomas S Wingo; Ekaterina S Gerasimov; Yue Liu; Duc M Duong; Selina M Vattathil; Adriana Lori; Jake Gockley; Michael S Breen; Adam X Maihofer; Caroline M Nievergelt; Karestan C Koenen; Daniel F Levey; Joel Gelernter; Murray B Stein; Kerry J Ressler; David A Bennett; Allan I Levey; Nicholas T Seyfried; Aliza P Wingo
Journal:  Mol Psychiatry       Date:  2022-04-21       Impact factor: 13.437

4.  Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms.

Authors:  Patricia T Spangler; James C West; Catherine L Dempsey; Kyle Possemato; Danielle Bartolanzo; Pablo Aliaga; Carlos Zarate; Meena Vythilingam; David M Benedek
Journal:  J Clin Psychiatry       Date:  2020-10-27       Impact factor: 4.384

5.  Mining Clinical Data for Novel Posttraumatic Stress Disorder Medications.

Authors:  Brian Shiner; Jenna A Forehand; Luke Rozema; Martin Kulldorff; Bradley V Watts; Marina Trefethen; Tammy Jiang; Krista F Huybrechts; Paula P Schnurr; Matthew Vincenti; Jiang Gui; Jaimie L Gradus
Journal:  Biol Psychiatry       Date:  2021-10-20       Impact factor: 13.382

6.  Barriers and facilitators to data quality of electronic health records used for clinical research in China: a qualitative study.

Authors:  Kaiwen Ni; Hongling Chu; Lin Zeng; Nan Li; Yiming Zhao
Journal:  BMJ Open       Date:  2019-07-02       Impact factor: 2.692

7.  SALM4 negatively regulates NMDA receptor function and fear memory consolidation.

Authors:  Eunkyung Lie; Yeji Yeo; Eun-Jae Lee; Wangyong Shin; Kyungdeok Kim; Kyung Ah Han; Esther Yang; Tae-Yong Choi; Mihyun Bae; Suho Lee; Seung Min Um; Se-Young Choi; Hyun Kim; Jaewon Ko; Eunjoon Kim
Journal:  Commun Biol       Date:  2021-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.